How Much Do GLP-1 Medications Actually Cost in 2026? A Complete Price Breakdown

GLP-1 pricing is one of the most confusing parts of starting treatment. The same medication can cost anywhere from $25 to $1,350 per month depending on your insurance, which savings programs you use, and whether you go through a telehealth platform. Here's a complete breakdown of every pricing option in 2026.

List Prices vs What You'll Actually Pay

List prices (what pharmacies charge before discounts) don't reflect what most people pay. Here's the full picture:

Manufacturer Savings Programs

Both major manufacturers offer significant savings cards. These are the most impactful way to reduce your cost if you have commercial insurance:

Novo Nordisk (Wegovy, Ozempic, Saxenda): If you have commercial insurance that covers your medication, savings cards can bring your copay down to $25 per fill. For uninsured patients, Novo Nordisk offered an introductory $199/month price for new patients through March 31, 2026 (0.25mg and 0.5mg starter doses). Text SAVE to 83757 for a digital savings card.

Eli Lilly (Zepbound, Mounjaro): With commercial insurance coverage, savings cards offer copays as low as $25 per fill (max $1,300/year). If your insurance doesn't cover Zepbound, the savings card price is $499/month. LillyDirect launched a self-pay vial program in February 2026 at $299-449/month depending on dose. All Lilly savings cards expire December 31, 2026.

Medicare Coverage: The $50/Month Program

This is the biggest cost development of 2026. CMS announced the Medicare GLP-1 Bridge Demonstration, launching July 2026:

• •Beneficiary copay: $50/month for GLP-1 medications
• •Negotiated manufacturer price: $245/month (paid by the program)
• •Covers Wegovy and Zepbound specifically
• •Eligibility: Medicare Part D enrollees meeting BMI criteria and related health conditions
• •Estimated ~10% of Medicare beneficiaries expected to qualify

The longer-term BALANCE Model is set to launch in January 2027 for Medicare and May 2026 for state Medicaid agencies that opt in. This combines GLP-1 access with lifestyle supports and allows CMS to negotiate drug pricing on behalf of participating plans.

Insurance Reality Check

Insurance coverage for GLP-1s is actually getting more restrictive for weight loss in 2026, despite growing demand:

• •8.5% of commercially insured people (16+ million) have no GLP-1 coverage for weight loss at all
• •The number of people without Wegovy coverage specifically increased 42% vs 2025 — over 41 million without access
• •Major insurers including BCBS, Cigna, and UnitedHealthcare implemented new restrictions as of January 2026, mostly limiting coverage to Type 2 diabetes only
• •Most insurers still cover Ozempic/Mounjaro for diabetes — restrictions primarily hit weight-loss-only indications

Telehealth Platform Pricing

Online telehealth providers often offer lower total costs by bundling consultation fees with medication. Here's a sample of what platforms charge:

We rank 30+ telehealth GLP-1 providers by price on our cheapest providers page. Many of the providers listed on our site offer competitive all-inclusive pricing.

FSA/HSA: Yes, GLP-1s Qualify

GLP-1 medications are FSA and HSA eligible when prescribed for a documented medical condition (obesity, Type 2 diabetes, metabolic syndrome). This applies to all brand-name GLP-1s, compounded versions with a valid prescription, and in many cases the telehealth consultation fees as well. You'll need a valid prescription and medical documentation — purely cosmetic weight loss without a medical diagnosis may not qualify.

Medicaid: Coverage Is Shrinking

As of January 2026, only 13 state Medicaid fee-for-service programs cover GLP-1s for obesity treatment — down from 16. California, New Hampshire, Pennsylvania, and South Carolina recently eliminated coverage. Michigan added strict requirements including morbid obesity classification and documented failure of other interventions.

The BALANCE Model allows state Medicaid agencies to opt in starting May 2026, with CMS negotiating drug pricing on their behalf. This could expand access, but it's voluntary.